The Center for Personalized Diagnostics at the University of Pennsylvania Perelman School of Medicine has launched two next-gen sequencing-based gene panels for cancer patients and is studying their utility compared to single-gene tests as well as exome and genome sequencing.

The center, founded last year, is a collaboration between the Department of Pathology and Laboratory Medicine, where it is currently housed, and UPenn's Abramson Cancer Center. Early this summer, the CPD will move into a larger space that will enable it to expand.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.